295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Growth of digital healthcare stabilised in 2023 The growth in the use of digital healthcare tools by care providers stabilised in 2023. This was mainly because most care providers were already using particular digital tools in 2022, such as the patient portal – on which patients can view the outcomes of examinations – and e-consultations (digital written contact with doctors).
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
Use of e-health increases but not always effective 2021 saw an increase in the use of e-health in every part of the healthcare industry in comparison with 2019. There were several reasons for this, including the coronavirus pandemic.
Safety of materials and products already starts at the design phase The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.